Perceptive Advisors has noticed an uptick of investor interest in the life sciences sector as it held the final close for its latest venture capital fund at $515 million.
The Perceptive Xontogeny Venture Fund II was oversubscribed and furthers the New York-based group’s early-stage life sciences platform. The close of PXV Fund II triples the assets under management to $725 million in less than two years of the closing of the inaugural fund.
The fund’s strategy complements Perceptive Advisors’ Life Sciences hedge fund and credit opportunities funds in that it will . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.